Summit Therapeutics Inc. · NASDAQ:SMMT
Summit Therapeutics — 44th Annual J.P. Morgan Healthcare Conference 2026
15 slides from Summit Therapeutics's conference presentation, Jan 12, 2026
Slide 1: 44th Annual J.P. Morgan Healthcare Conference
44th Annual J.P. Morgan Healthcare Conference January 12, 2026 BOB DUGGAN Chairman & Co-Chief Executive Officer DR. MAKY ZANGANEH President & Co-Chief Executive Officer
Slide 2: Forward Looking Statement
Forward Looking Statement Any statements in this presentation about the Company’s future expectations, plans of data from ongoing and future clinical trials, the results of such trials, and their and prospects, including but not limited to, statements about the clinical and success, global public he
Slide 3: SUBMITTED! BLA for Ivonescimab in 2L+ EGFRm NSCLC
Anti-VEGF SUBMITTED! Anti-PD-1 US Biologics License Application (BLA) Submitted to the FDA in the Fourth Ivonescimab + Chemo vs. Chemo Quarter 2025 in 2L+ EGFRm NSCLC Abbreviations: 2L+=second-line or later line; Chemo=Chemotherapy; EGFRm=epidermal growth factor receptor mutation-positive; FDA=US Fo
Slide 4: Ivonescimab: PD-1 x VEGF Class Frontrunner with Multi-Year Lead
Ivonescimab Includes both Summit and Akeso trials Anti-VEGF PD-1 x VEGF Class Frontrunner with Multi-Year Lead Anti-PD-1 Mission: Patients First To improve quality of life, increase 4 Positive Phase III 2 Indications Approved in China Readouts to Date Chinese Approvals potential duration of life, by
Slide 5: Cooperative Binding
Anti-VEGF Cooperative Binding Potentially Drives Synergistic Increased Avidity in TME Anti-Tumor Activity Presence of VEGF-A efficiently enhances the binding affinity to PD-1 by several fold1 (in vitro) Anti-PD-1 Enhanced Activity of T Cells VEGF dimer leads to potential interconnection of ivonescim
Slide 6: Ivonescimab Development: Summit + Akeso Pipelines
Ivonescimab Development: Summit + Akeso Pipelines TUMOR TYPE STUDY LINE & INDICATION REGIMEN PHASE STATUS 1/1b 2 3 Approved 2L advanced EGFRm+ NSCLC ivonescimab + chemo vs. placebo + chemo Active, Recruiting Complete Lung 1L metastatic NSCLC ivonescimab + chemo vs. pembrolizumab + chemo Recruiting 1
Slide 7: Ivonescimab Development Plan and Summit Pipeline
Ivonescimab Development Development:Plan Summit Pipeline Phase I and II trials completed by Akeso. Collaborations Collaborations RASi >60 ISTs >60Supported ISTs 1 1 46 >46 RevMed: Novel RAS(ON)i: NSCLC, PDAC, CRC 15 Currently Enrolling Ivonescimab Posters, GSK: Novel B7-H3: multi-tumor incl. SCLC Mo
Slide 8: Four Phase III Clinical Studies with Positive Results
Ivonescimab Anti-VEGF Four Phase III Clinical Studies with Positive Results Anti-PD-1 1L NSCLC 2L+ EGFRm NSCLC Ivonescimab vs. Anti-PD-1 +/- chemo Ivonescimab + Chemo vs. Placebo + Chemo PD-L1 Positive, Monotherapy Squamous, PD-L1 All-Comers EGFRm after a TKI EGFRm after a 3rd-gen TKI Ivonescimab vs
Slide 9: Three Settings: Four Phase III Studies with Positive Results
Three Settings: Four Phase III Studies with Positive Results (2L+, EGFR+) (1L, PD-L1+) (1L, squamous) HR=0.52 HR=0.51 HR=0.60 (95% CI: 0.41-0.66, (95% CI: 0.38-0.69, (95% CI: 0.46-0.78, p<0.0001) p<0.0001) p<0.0001) V Ivonescimab + Placebo + Ivonescimab PD-1 (pembrolizumab) Ivonescimab PD-1 (tisleli
Slide 10: Ivonescimab Milestones Achieved
2025 2024 Data, iOS: Ph3 1L NSCLC PD-L1+ (China)6,7 NMPA Approval: 1L NSCLC PD-1+ (China) Ivonescimab Milestones Data, PFS, iOS: Ph3 2L+ EGFRm NSCLC (China) 4,5 NMPA Approval: 2L+ EGFRm NSCLC (China) Data, PFS: Ph3 1L NSCLC SQ (China) @ ESMO8,9 Achieved Trial Amendment: Ph3 1L NSCLC: Initiation of D
Slide 11: Ivonescimab Clinical Questions Answered in 2025
Ivonescimab Clinical Global Questions Answered in 2025 China Ivo monotherapy: clinically Potential for positive Potential for positive results Potential for meaningful positive early PFS OS trend monotherapy results to be from China studies to data to translate vs. pembro to positive monotherapy sus
Slide 12: Shaping the Path to Become a Commercial Entity
Shaping the Path to Become a Commercial Entity 1Q26 Further details beginning this quarter on new global Phase IIIs Anti-VEGF 1H26 HARMONi-3 SQ: Completion of enrollment expected HARMONi-3 SQ: PFS, interim OS data readout expected 2H26 HARMONi-3 nSQ: Completion of enrollment expected Anti-PD-1 HARMO
Slide 13: Strong Balance Sheet to Kick Off 2026
Strong Balance Sheet to Kick Off 2026 ~$710M Unaudited Cash as of 12/31/2025 $0 No Debt as of 12/31/2025 Summit Proprietary Information - Do Not Copy or Distribute Ivonescimab is an investigational therapy not presently approved by any regulatory 13 JPM 2026 Presentation | 1/2026 authority other tha
Slide 14: Platform Opportunity
Platform Opportunity Checkpoint Inhibitor Global Market >$90B >$20B NSCLC in 20282 Potential growth PD-(L)1: >$50B in 20243 beyond $30B pembrolizumab in 20244 >50 current approved >$110B PD-(L)1 & indications1 + VEGF for PD-(L)1 Inhibitors + indications VEGF Inhibitors VEGF Inhibitor Global Market E
Slide 15: Management Team
Bob Duggan Dr. Maky Zanganeh Manmeet Soni Dave Gancarz Chairman & Co-Chief President & Co-Chief Chief Operating Chief Business & Executive Officer Executive Officer Officer & Chief Strategy Officer Financial Officer Dr. Allen Yang Dr. Fong Clow Dr. Urte Gayko Dr. Jack West Chief R&D Chief Biometrics
Summit Therapeutics — 44th Annual J.P. Morgan Healthcare Conference 2026 on 6ix